Literature DB >> 8943473

Expression of TGF-beta 1 and matrix proteins is elevated in rats with chronic rejection.

F S Shihab1, A M Tanner, Y Shao, M I Weffer.   

Abstract

The pathogenesis of fibrosis in chronic renal allograft rejection remains unknown. Since TGF-beta 1 plays a key role in fibrogenesis, we studied a rat model of chronic allograft rejection that shows similarities to the structural lesion described in patients. We previously demonstrated an increased expression of TGF-beta 1 in human kidney biopsies with acute and chronic rejection. Recipients of renal allografts (F344-Lewis) and isografts (Lewis-Lewis) were sacrificed at 4, 8, 24 and 52 weeks. Characteristic histologic changes of chronic rejection developed in the allografts as early as four weeks and were accompanied by progressive albuminuria significant by eight weeks. Allografts showed a progressive increase in mRNA expression of TGF-beta 1 and matrix proteins during the 52 week course. Increased matrix deposition by immunofluorescence was mostly present in the interstitium and vessels early and in all kidney compartments later. The mRNA expression of plasminogen activator inhibitor, a protease inhibitor stimulated by TGF-beta 1, increased along with TGF-beta 1 and matrix proteins. These results suggest that the fibrosis of chronic renal allograft rejection is mediated, at least partly, by the dual action of TGF-beta 1 on matrix deposition and degradation.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8943473     DOI: 10.1038/ki.1996.512

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  9 in total

Review 1.  Is RAS blockade routinely indicated in hypertensive kidney transplant patients?

Authors:  Daniel J Salzberg
Journal:  Curr Hypertens Rep       Date:  2007-11       Impact factor: 5.369

2.  Antibodies against mesangial cells and their secretory products in chronic renal allograft rejection in the rat.

Authors:  L C Paul; J Muralidharan; S A Muzaffar; E H Manting; J F Valentin; E de Heer; M Kashgarian
Journal:  Am J Pathol       Date:  1998-05       Impact factor: 4.307

3.  Late blockade of T cell costimulation interrupts progression of experimental chronic allograft rejection.

Authors:  A Chandraker; H Azuma; K Nadeau; C B Carpenter; N L Tilney; W W Hancock; M H Sayegh
Journal:  J Clin Invest       Date:  1998-06-01       Impact factor: 14.808

Review 4.  Immunosuppressant-induced nephropathy: pathophysiology, incidence and management.

Authors:  A J Olyaei; A M de Mattos; W M Bennett
Journal:  Drug Saf       Date:  1999-12       Impact factor: 5.606

5.  13-cis retinoic acid inhibits development and progression of chronic allograft nephropathy.

Authors:  Judith Adams; Eva Kiss; Ana B V Arroyo; Mahnaz Bonrouhi; Qiang Sun; Zhen Li; Norbert Gretz; Anna Schnitger; Christos C Zouboulis; Manfred Wiesel; Jürgen Wagner; Peter J Nelson; Hermann-Josef Gröne
Journal:  Am J Pathol       Date:  2005-07       Impact factor: 4.307

6.  A critical role for transforming growth factor-beta in donor transfusion-induced allograft tolerance.

Authors:  R Josien; P Douillard; C Guillot; M Müschen; I Anegon; J Chetritt; S Menoret; C Vignes; J P Soulillou; M C Cuturi
Journal:  J Clin Invest       Date:  1998-12-01       Impact factor: 14.808

7.  Urinary proteomic shotgun approach for identification of potential acute rejection biomarkers in renal transplant recipients.

Authors:  Håvard Loftheim; Karsten Midtvedt; Anders Hartmann; Anna V Reisæter; Pål Falck; Hallvard Holdaas; Trond Jenssen; Leon Reubsaet; Anders Asberg
Journal:  Transplant Res       Date:  2012-08-31

8.  Effect of losartan on Doppler sonography indices in kidney transplant patients: a randomized clinical trial.

Authors:  Nader Nouri-Majalan; Reza Nafisi; Sarasadat Moghadasi-Mousavi
Journal:  Vasc Health Risk Manag       Date:  2009-04-08

9.  Wnt pathway activation in long term remnant rat model.

Authors:  E Banon-Maneus; J Rovira; M J Ramirez-Bajo; D Moya-Rull; N Hierro-Garcia; S Takenaka; F Diekmann; O Eickelberg; M Königshoff; J M Campistol
Journal:  Biomed Res Int       Date:  2014-06-05       Impact factor: 3.411

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.